Charles River's Parkinson's disease model platform uses manipulation of the unilateral 6-hydroxydopamine (6-OHDA) model in order to take into account both acute and symptomatic effects of Parkinson's disease. In addition, we have, as the product of its own in-house validations, a MPTP model available.
Models for Parkinson's Disease
- 6-OHDA Medial Forebrain Bundle Model
- 6-OHDA Striatal Model
- MPTP Model
Example Study Paradigm of 6-OHDA Striatal Model
Click here to see a diagram outlining an example study paradigm using our 6-OHDA Striatal model.
Quantification of tyrosine hydroxylase (TH) postivie neurons in substantia nigra (SNc) at 14 days after MPTP challenge
Quantification of Dopamine (DA) content in striatum by HPLC at14 days after MPTP challenge
Amphetamine-Induced net rotational activity in 6-OHDA median forebrain bundle lesioned rats over time
Tyrosine hydroxylase postive neurons in substantia nigra (SNc)
For more information about our models used to research Parkinson’s disease, please contact us at firstname.lastname@example.org.
Charles River also offers an in vitro Parkinson’s disease model. For more information, click here.